| 0.9431 0.101 (11.95%) | 11-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.27  |
1-year : | 3.11 |
| Resists | First : | 1.94 |
Second : | 2.67 |
| Pivot price | 0.97 |
|||
| Supports | First : | 0.77 | Second : | 0.64 |
| MAs | MA(5) : | 0.85  |
MA(20) : | 1.26 |
| MA(100) : | 2.62 |
MA(250) : | 3.27 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 8.9 |
D(3) : | 4.6 |
| RSI | RSI(14): 29.6 |
|||
| 52-week | High : | 6.15 | Low : | 0.77 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CATX ] has closed above bottom band by 45.0%. Bollinger Bands are 17.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.97 - 0.97 | 0.97 - 0.97 |
| Low: | 0.85 - 0.85 | 0.85 - 0.85 |
| Close: | 0.94 - 0.94 | 0.94 - 0.95 |
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Fri, 13 Nov 2026
Form 4 Perspective Therapeutics Inc: Markus Puhlmann (Chief Medical Officer) For: 11 November By Investing.com - Investing.com India
Tue, 10 Nov 2026
Perspective Therapeutics, Inc. (CATX) latest stock news and headlines - Yahoo Finance UK
Fri, 23 Oct 2026
With 72% alive without cancer progression at 18 months, Perspective Therapeutics (CATX) plans its next trial. - Stock Titan
Fri, 23 Oct 2026
Half of one group had tumor responses, including unconfirmed cases, in a cancer trial. - Stock Titan
Fri, 23 Oct 2026
Perspective Therapeutics Reports VMT-α-NET Responses of 33% and 50% in Phase 1/2a Trial - TradingView
Tue, 08 Sep 2026
Perspective Therapeutics (CATX) highlights 3 cancer drug programs - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|